Anti-MGLUR2-Biparatopische Nanokörper und deren Verwendungen

Details

Veröffentlichungs-Nr.

EP4299125

Aktenzeichen

EP22305967

Anmeldetag

30. Juni 2022

Veröffentlichung

3. Januar 2024

Rechtsraum

EP

IPC

A61P25/00A61K51/10C07K16/28A61K39/395

Abstract

The present invention relates to a biparatopic nanobody comprising :(i) one single domain antibody havinga CDR1 having a sequence set forth as SEQ ID NO:1, a CDR2 having a sequence set forth as SEQ ID NO:2and a CDR3 having a sequence set forth as SEQ ID NO:3; or a CDR1 having a sequence set forth as SEQ ID NO:4, a CDR2 having a sequence set forth as SEQ ID NO:5 and a CDR3 having a sequence set forth as SEQ ID NO:6; or a CDR1 having a sequence set forth as SEQ ID NO:7, a CDR2 having a sequence set forth as SEQ ID NO:8 and a CDR3 having a sequence set forth as SEQ ID NO:9; preferablya CDR1 having a sequence set forth as SEQ ID NO:1, a CDR2 having a sequence set forth as SEQ ID NO:2 and a CDR3 having a sequence set forth as SEQ ID NO:3; and(ii) another single domain antibody havinga CDR1 having a sequence set forth as SEQ ID NO:10, a CDR2 having a sequence set forth as SEQ ID NO:11 and a CDR3 having a sequence set forth as SEQ ID NO:12; ora CDR1 having a sequence set forth as SEQ ID NO:13, a CDR2 having a sequence set forth as SEQ ID NO:14 and a CDR3 having a sequence set forth as SEQ ID NO:15; or a CDR1 having a sequence set forth as SEQ ID NO:16, a CDR2 having a sequence set forth as SEQ ID NO:17 and a CDR3 having a sequence set forth as SEQ ID NO:18.

Anmelder

Firmen

UNIVERSITE DE MONTPELLIER
Centre National de la Recherche Scientifique (CNRS)
Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut Jean Paoli & Irène Calmettes
Université d'Aix Marseille

Land

🇫🇷 Frankreich

Fachgebiete